Cited by

• Risk of SARS-CoV-2 infection following initial COVID-19 vaccination: Population-based cohort study.

  Tadrous M, Chung H, Men S, Chu C, Campbell T, Juurlink DN, Kwong JC, Paterson JM, Gomes T. Tadrous M, et al. PLoS One. 2022 Oct 20;17(10):e0273903. doi: 10.1371/journal.pone.0273903. eCollection 2022. PLoS One. 2022. PMID: 36264950 Free PMC article.
• Salivary SARS-CoV-2 antibody detection using S1-RBD protein-immobilized 3D melt electrowritten poly(ε-caprolactone) scaffolds.

  Han P, Liu C, Staples R, Moran CS, Ramachandra SS, Gómez-Cerezo MN, Ivanovski S. Han P, et al. RSC Adv. 2022 Aug 31;12(38):24849-24856. doi: 10.1039/d2ra03979f. eCollection 2022 Aug 30. RSC Adv. 2022. PMID: 36128389 Free PMC article.
• Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study.

  Hu Z, van der Ploeg K, Chakraborty S, Arunachalam PS, Mori DAM, Jacobson KB, Bonilla H, Parsonnet J, Andrews JR, Holubar M, Subramanian A, Khosla C, Maldonado Y, Hedlin H, de la Parte L, Press K, Ty M, Tan GS, Blish C, Takahashi S, Rodriguez-Barraquer I, Greenhouse B, Butte AJ, Singh U, Pulendran B, Wang TT, Jagannathan P. Hu Z, et al. Elife. 2022 Oct 14;11:e77943. doi: 10.7554/eLife.77943. Elife. 2022. PMID: 36239699 Free PMC article.
• A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses.

  Tauzin A, Nayrac M, Benlarbi M, Gong SY, Gasser R, Beaudoin-Bussières G, Brassard N, Laumaea A, Vézina D, Prévost J, Anand SP, Bourassa C, Gendron-Lepage G, Medjahed H, Goyette G, Niessl J, Tastet O, Gokool L, Morrisseau C, Arlotto P, Stamatatos L, McGuire AT, Larochelle C, Uchil P, Lu M, Mothes W, De Serres G, Moreira S, Roger M, Richard J, Martel-Laferrière V, Duerr R, Tremblay C, Kaufmann DE, Finzi A. Tauzin A, et al. Cell Host Microbe. 2021 Jul 14;29(7):1137-1150.e6. doi: 10.1016/j.chom.2021.06.001. Epub 2021 Jun 4. Cell Host Microbe. 2021. PMID: 34133950 Free PMC article.
• The Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis.

  Shaker M, Phillips E, Blumenthal KG, Abrams EM, Banerji A, Oppenheimer J, Vander Leek TK, Mack DP, Wickner PG, Singer AG, Khan DA, Greenhawt M. Shaker M, et al. J Allergy Clin Immunol Pract. 2021 Jul;9(7):2556-2561. doi: 10.1016/j.jaip.2021.04.015. Epub 2021 Apr 20. J Allergy Clin Immunol Pract. 2021. PMID: 33892171 Free PMC article.